GENEVA, February 3 /PRNewswire/ -- Viroblock SA, a start-up dedicated to developing and commercializing a new generation of anti-viral products, today announced that Dr. Jamie Paterson will join Viroblock as Chief Executive Officer (CEO).
Jamie Paterson, a British national, can look back at 20 years of experience in the pharmaceutical industry. Prior to joining Viroblock he was Chief Commercial Officer at Neurim Pharmaceuticals. During his 18 years at Procter Gamble he held several positions with increasing responsibility including Marketing Manager Italy and Commercial Director Spain. His final position at PG was European Director of Strategic Planning and New Business Development - Rx OTC. Jamie holds a PhD in Biochemistry from Imperial College, University of London.
I welcome Jamie as our new CEO and I am pleased to concentrate my activities to further demonstrate scientifically the potential of our technology in several viral indications said Thierry Pelet who is one the co-founders of the company. Thierry will assume the position of Chief Science Officer (CSO).
Viroblock further announced that it has completed its second round of equity funding. The Series B financing round was led by Fongit Seed Invest SA. Peter Pfister, Initiative Capital Romandie SA (managed by DEFI Gestion) and BlueOcean Ventures acted as co-investors.
With Jamie and Thierry we have a strong leadership team with proven business skills and accomplished scientific know-how. This team equipped with the additional funding can now start developing our first anti-viral products, which will bring the company to the next level, said Peter Pfister, Chairman of the Board.
About Viroblock
Viroblock is dedicated to developing and commercializing a new generation of anti-viral products with a novel mechanism of action against enveloped viruses. Enveloped viruses represent more than 60% of all existing viruses and include major human pathogens such as human and avian influenzas, the hepatitis B and C viruses and the AIDS virus.
Viroblock's unique proprietary products and technologies open very promising opportunities in a number of prophylactic and therapeutic applications.
Viroblock was founded in October 2005 by the late Donald Wallach, a scientist and academic with past tenure at the Harvard Medical School and Tufts University, and a pioneer in the research of liposome systems.
For more information: Thierry Pelet +41-22-884-8344 info@viroblock.com
SOURCE: Viroblock SA
CONTACT: For more information: Thierry Pelet, +41-22-884-8344,info@viroblock.com
Comments